Last reviewed · How we verify
NCT03951012
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
trial testing Blood draw in Non Small Cell Lung Cancer in 29 participants. Terminated before completion.
30 August 2022
Quick facts
| Lead sponsor | Muhammad Furqan |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 29 |
| Start date | 15 April 2019 |
| Primary completion | 30 August 2022 |
| Estimated completion | 8 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Blood draw — full drug profile →
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
Muhammad Furqan
Who can join
Adults 18 to 100, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Peripheral blood contains enormous quantity of biological information that can improve our patient care. Investigators plan to use proteomics from serum to study its value in predicting the therapeutic response and toxicities of immunotherapy in non-small cell lung cancer (NSCLC).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03951012
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood draw
Trials testing the same drug.
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
- NCT07252622 — Progesterone Levels and Frozen Embryo Transfer Outcomes · not yet recruiting
- NCT07382076 — Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population · active not recruiting
- NCT06011824 — A Study of Effect of Megakaryocytes and Platelets in Breast Cancer · completed
- NCT05912400 — Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1 · completed
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Muhammad Furqan trials
Trials by the same sponsor.
- NCT02769832 — Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03951012 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muhammad Furqan
- Last refreshed: 12 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951012.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing